Sage Journals: Discover world-class research

Abstract

Multimorbidity, the presence of 1+ chronic condition in an individual, remains one of the greatest challenges to health on a global scale. Although the prevalence of multimorbidity has been well-established, its incidence is not fully understood. This systematic review determined the incidence of multimorbidity across the lifespan; the order in which chronic conditions accumulate to result in multimorbidity; and cataloged methods used to determine and report accumulation of chronic conditions resulting in multimorbidity. Studies were identified by searching MEDLINE, Embase, CINAHL, and Cochrane electronic databases. Two independent reviewers evaluated studies for inclusion and performed quality assessments. Of 36 included studies, there was high heterogeneity in study design and operational definitions of multimorbidity. Studies reporting incidence (n = 32) reported a median incidence rate of 30.7 per 1,000 person-years (IQR 39.5 per 1,000 person-years) and a median cumulative incidence of 2.8% (IQR 28.7%). Incidence was notably higher for persons with older age and 1+ chronic conditions at baseline. Studies reporting patterns in accumulation of chronic conditions (n = 5) reported hypertensive and heart diseases, and diabetes, as among the common starting conditions resulting in later multimorbidity. Methods used to discern patterns were highly heterogenous, ranging from the use of latent growth trajectories to divisive cluster analyses, and presentation using alluvial plots to cluster trajectories. Studies reporting the incidence of multimorbidity and patterns in accumulation of chronic conditions vary greatly in study designs and definitions used. To allow for more accurate estimations and comparison, studies must be transparent and consistent in operational definitions of multimorbidity applied.

Keywords

Multimorbidity systematic review incidence epidemiology accumulation

Introduction

Multimorbidity continues to increase world-wide, presenting one of today’s biggest challenges to individual and population health, and to health systems.^1,2 Multimorbidity results in poorer patient outcomes^3,4 and excess mortality.^5–20 Patients with multimorbidity also present with unique medical care needs; while specialized treatment approaches are appropriate for single diseases, patients with multimorbidity require complex and structured care plans.²¹ This poses substantial impacts on disease management, healthcare utilization, and costs.^22–24 The study of multimorbidity, and its epidemiology, may help in better understanding its development; determine reasons for variations in patient outcomes; and design targeted interventions to manage adverse outcomes of multimorbidity.^25–27

Existing literature on the epidemiology of multimorbidity has increased substantially, moving from a nascent body of evidence in the 1970s to a now well-established and distinct field of research. Consistent with a growing area of study, the epidemiological research was concerned first with defining multimorbidity and summarizing studies concerning its prevalence.^26,28 Determining prevalence has permitted us to quantify the burden of multimorbidity in populations and health care systems. However, prevalence is limited in its ability to tell us when and why people accumulate multimorbidity. In order to better understand the etiology of multimorbidity and to project the healthcare needs of patients with multimorbidity, we must turn our attention to determining its incidence.

The incidence of multimorbidity is, by definition, the incidence of multiple chronic conditions that are accumulated in a particular order. Therefore, it is important to study both the incidence of multimorbidity and the accumulation of its component chronic conditions. Currently, there is a growing body of research addressing incidence of multimorbidity. As well, there is emerging literature using innovative and heterogenous methods to describe the accumulation of chronic conditions in multimorbidity. Our goal was to summarize available evidence on the incidence of multimorbidity across the lifespan. More specifically, our objectives were: 1. to determine the incidence of multimorbidity overall and by age groups, including children; 2. to determine the order in which people accumulate the component chronic conditions leading to multimorbidity; and 3. to catalog the methods used to assess and report accumulation.

Methods

We conducted a systematic review (registered in PROSPERO, reference no. CRD42020191876) in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and checklist (Supplementary Table S1).²⁹ An a priori review process was established and followed; this protocol was not published. As this was a systematic review of literature, Research Ethics Board review or approval was not required. There were no participants or patients enrolled and so no consent was needed for participation, or for patient information and images to be published.

Literature search strategy

Following the recommendation from Chapter 4: Searching for and Selecting Studies in the Cochrane Handbook for Systematic Reviews of Interventions,³⁰ searches of the health-related bibliographic databases, MEDLINE, Embase, CINAHL, and The Cochrane Library were undertaken by the Health & Medicine Librarian (MS1), utilizing both free-text and subject headings (MeSH) to identify an initial batch of relevant and eligible studies reporting incidence of multimorbidity and/or patterns in accumulation of chronic conditions. Databases were searched from inception to May 26, 2020.

Search terms used in the database query for multimorbidity, with its various spelling, were “multimorbidity,” “multi-morbidity,” “multimorbidities,” “multi-morbidities,” “multiple morbidities,” “multiple-morbidities,” “multiple chronic diseases” and “multiple chronic conditions.” We searched for incidence and accumulation and their different meanings, using “inciden*,” “accumulat*,” “trajector*,” “longitudinal,” “acquire,” “acquisition,” “predict*,” “cohort,” and “epidemiology.” The full search strategy is provided in Supplementary Table S2.

Study selection

After removing duplicates, titles and abstracts of initial search results were screened by the two reviewers (PK, BS) independently for eligibility. Reviewers initially screened two sets of 10 articles and discussed decisions with the senior study coordinator (BLR) to ensure consistency in applying selection criteria. Eligible articles included peer-reviewed studies using primary or secondary quantitative analyses, including mixed methods studies, published in English and/or French language. Studies with participants of all ages, including children, and specifically reporting 1. incidence of multimorbidity and/or 2. patterns in accumulation of chronic conditions as primary or secondary outcomes, were included. Conference presentations, books, letters, editorials, non-human literatures, and abstract-only studies were excluded. Articles deemed suitable for full-text review were identified and full-texts were then reviewed to confirm eligibility criteria by the two reviewers first independently and then collaboratively to reach consensus. Studies which still satisfied inclusion and exclusion criteria upon full-text review were selected for data extraction. Disagreements were initially discussed by reviewers for resolution. The study coordinator worked with reviewers to resolve any disagreement through consensus. Within the articles identified for review, reference lists were hand-searched for additional articles meeting our criteria.

Quality assessment

The two reviewers independently performed quality assessment using the Newcastle-Ottawa Scale (NOS) for assessing study methodology of non-randomized studies.³¹ NOS assessment guidelines were followed and, where dictated by NOS guidelines, some assessment criteria were further defined by study authors as described in Supplementary Table S3. Randomized controlled trials (RCTs) were assessed for study methodology and risk of bias (RoB) using the Cochrane Collaboration’s RoB tool.³² Of the 36 included studies, 35 observational studies and one RCT underwent quality and risk of bias assessment (Supplementary Table S4). Individual NOS ratings were converted to Agency for Healthcare Research and Quality (AHRQ) standards as one of three levels: Good, Fair, and Poor. A priori scores to exclude studies of low quality were not established in order to include the entire landscape of literature in this review; as such, studies of all scores were included.

Data extraction

The two reviewers independently extracted data from eligible studies following full-text review. A comprehensive data extraction sheet was developed to collect data pertaining to: study characteristics (authors, date of publication, study design, geographic locations, data collection period, follow-up period, data sources, sample size, populations of interest); sample demographics (ages, sex and/or gender, race and/or ethnicity, body mass index (BMI), education levels, smoking status, alcohol consumption levels, physical activity levels, and marital statuses); definitions of multimorbidity; number and selection of conditions included in definitions of multimorbidity; incidence rates and/or cumulative incidences of multimorbidity; patterns in accumulation of chronic conditions; methods used in accumulation studies; and risk factors for multimorbidity. The sheet was pilot tested using three studies. The two reviewers then reconciled any differences, consulting the senior study coordinator as required. Study authors were contacted by email for further information as needed for clarification.

Incidence data were recorded in separate tables for studies reporting incidence rates (IRs) and for studies reporting cumulative incidence. IRs were extracted as the number of incident cases per 1,000 person-years. Results from studies not already reporting per 1,000 person-years were adjusted to meet this format. Cumulative incidence was extracted as a percentage. Results from studies not providing percentages were standardized to meet this format by dividing the incident cases by the number of baseline participants without multimorbidity and multiplying by 100. When multiple IRs were reported, overall IRs across the population were reported in tables if available; additional IRs were not reported; however, in the tables, the availability of additional IRs is noted. If overall IR or cumulative incidence was not available, incidences provided by study authors were presented in the following priority, as available: by age, sex and/or gender, other demographics.

Results

Overview of studies

The process used for study selection is reported in the PRISMA flow diagram (Figure 1) and PRISMA checklist³³ (Supplementary Table S1). We identified 4,579 studies from the initial database searches; all were published between 1976 and 2020. After removing duplicates and non-original articles, 2,926 studies were identified, of which 109 were retained for full-text screening. A total of 73 articles were excluded following full-text review or qualitative synthesis,^34–106 with reasons; the majority of excluded studies were those that did not report incidence of multimorbidity; reported incidence of specific chronic conditions and not of multimorbidity; and/or did not account for temporal components when determining patterns in accumulation of chronic conditions, amongst other reasons. Of the articles that underwent full-text review, 36 studies were included in further synthesis. No additional articles meeting our inclusion criteria were identified during hand-searches of study reference lists.

Figure 1.

PRISMA flow diagram for study selection.

Study quality and characteristics

Of the 35 observational studies, most studies (n = 26) were rated as Good quality according to AHRQ standards. Nine studies were ranked as Poor quality due to their omission of information regarding: representativeness of their data, ascertainment of exposure, controlled factors, assessment of outcome, adequacy of follow-up duration, case definition(s), case representativeness, selection strategy(ies), and/or non-response rate(s).^107–115 RoB assessment for the one RCT¹¹⁶ yielded low risk (Supplementary Table S5).

Of the 36 included studies, one examined both incidence and accumulation¹¹⁷; 31 studies reported only the incidence; and four studies reported only the accumulation of chronic conditions resulting in multimorbidity. Multimorbidity was defined as the presence of 2+ chronic conditions in all but six studies. Of these six, one study¹⁰⁷ defined multimorbidity as the co-occurrence of 3+ conditions and four^{111,116,118,119} did not specify a definition (Supplementary Table S6). However, all authors referenced consideration of 2+ conditions in their prose and/or tables. The number of chronic conditions used to identify multimorbidity varied extensively, ranging between 3 and 506. At the extremes, in one study of accumulation,¹¹⁷ three conditions were included (cancer, diabetes, and cardiovascular diseases); whereas, in another,¹¹⁸ 132 clusters of chronic conditions were included.

Table 1 reports the characteristics of the 32 studies that reported incidence of multimorbidity: 14 reported IR and 18 reported cumulative incidence. Studies were heterogeneous across all descriptive variables, including geographical location of study, data collection and follow-up periods, data sources, sample size and population, and demographics. The majority of studies reported either national or local incidence in high income (HIC) (n = 30) or middle income countries^108,120 (MIC) (n = 2). The majority of studies sourced data from a combination of sources,^{108,109,112–114,117,119–128} and sampled general populations,^{109,110,112–117,120,122,124,126,128–135} with the remainder focused on specific patient populations.^{25,107,108,119–121,136–138} Samples were generally larger for studies examining general populations. All except two^115,130 studies included different age groups across the lifespan. The majority of studies did not report race and/or ethnicity (n = 16/36), and, of those that did, there was heterogeneity in the terminology used to describe race and/or ethnicities.

Table 1.

Baseline characteristics for studies reporting incidence of multimorbidity (n = 32).

Study, year of publication	Country	Data collection period	Follow-up period^a	Data source	Sample size^b	Population	Age, years (range)^c	Female, n (%)	Ethnicity^d
Studies reporting incidence rates (n = 14)
Aminisani et al., 2019	New Zealand	2006–2016	10.0 years	Self-report (questionnaire)	1,673	General population	55–70	868 (52)	Māori, Non-Māori (European, Asian, Pacific persons, Other)
Bjur et al., 2019	USA	1999–2014	5.0 years	Medical records	1999 cohort: 31,390, 2004 cohort: 32,490, 2009 cohort: 32,942	General population	0–17	1999 cohort: 15,200 (48)^f, 2004 cohort: 15,814 (49)^f, 2009 cohort: 16,058 (49)^f	Non-Hispanic white, Other (African-American, Asian-American, Hispanic, Other and/or Unknown)
Castilho et al., 2019	Brazil	2003–2014	3.9 years	Medical records, laboratory values	6,121	Persons with HIV receiving ART	36.9 (median)^e	2,027 (33)	White, Mixed Black or Black, Other/Unknown/Missing
Castilho et al., 2020	USA	1998–2015	No mood disorder at baseline: 4.9 years (mean), Mood disorder at baseline: 5.1 years (mean)	Medical records	No mood disorder: 2,487, Mood disorder: 725	Persons with HIV	No mood disorder at baseline: 38.7 (median)^e, Mood disorder at baseline: 40.1 (median)^e	953 (23)^f	White, Black, Other
Chan et al., 2019	United Kingdom	2001–2010	5.5 years (mean)	Medical records	844,838	Primary care	≥45^e	595,176 (53)^f	Not specified
Dhalwani et al., 2016	United Kingdom	2008–2013	232,749 person-months	Self-report (survey), clinical evaluation	5,476	General population	≥50	2,901 (53)	White, Non-White
Dugravot et al., 2020	United Kingdom	1985–2017	23.6 years (median)	Self-report (questionnaire), clinical evaluation	6,425	British civil servants	35–55^e	1,848 (29)	White, Other
Freisling et al., 2020	Denmark, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom	1992–2010	11.0 years (median)	Self-report (questionnaire), medical records, health insurance records	291,778	General population	43–58 (median)	186,564 (64)	Not specified
Hussin et al., 2019	Malaysia	2014–2016	1.5 years	Self-report (interviews)	729	General population	≥60	363 (49)	Malay, Chinese, Indian
Kivimäki et al., 2017	USA, United Kingdom, Finland, France, Sweden, Austria, Belgium, Germany, Denmark, Spain, Italy, Netherlands, Israel	1995–2014	10.7 years (mean)	Self-report (survey), medical records	120,813	Persons with overweight and/or obesity	35–103	71,445 (59)	White, Non-White
Lau et al., 2019	Malaysia	2012–2016	3.0 years	Self-report (questionnaire), interview	738	General population	≥60^e	813 (52)^f	Malay, Chinese, Indian, Others
Licher et al., 2019	Netherlands	1989–2012	75,354 person-years	Medical records, interview	9,061	General population	45–107	5,458 (60)	Not specified
Melis et al., 2014	Sweden	1991–1993	3.0 years	Medical records	390	General population	≥78	292 (75)	White
St Sauver et al., 2015	USA	2000–2013	14.0 years	Medical records	106,061	General population	All ages	53,582 (43)	White, Black, Asian
Studies reporting cumulative incidence (n = 18)
Demirchyan et al., 2013	Armenia	1990–2012	22.0 years	Self-report (survey), clinical evaluation	597	Survivors of the 1988 Armenian earthquake	39–90^e	491 (68)^f	Not specified
Guaraldi et al., 2015	Italy	2003–2014	8,206 person-years	Medical records, clinical evaluation, laboratory values	2,383	Persons with HIV	46 (mean)^e	867 (32)^f	Not specified
Hohmann et al., 2019	Sweden, Netherlands, Germany	Not specified	4–20 years following birth	Self-report (questionnaire)	18,451	General population from 5 birth cohorts	4–20	9,040 (49)	Not specified
Marengoni et al., 2018	Finland	2009–2011	2.0 years	Self-report (questionnaire)	489	General population	60–77^e	499 (47)^f	Not specified
Mounce et al., 2018	United Kingdom	2002–2013	10.1 years (mean)	Self-report (interview), clinical evaluation	3,011	General population	≥50	1,593 (53)	Not specified
Niedzwiedz et al., 2019	USA	2008–2014	6.0 years	Self-report (questionnaire), laboratory values	1,989	General population	50–100^e	1,173 (59)	Non-Hispanic White, Non-Hispanic Black, Hispanic, Other
Ryan et al., 2018	Ireland	2010–2012	2.0 years	Self-report (questionnaire), clinical evaluation	2,235	General population	≥50	1,120 (50)	Not specified
Salloum et al., 2019	USA, Canada	1970–1999	15.0 years	Medical records, self-report (questionnaire)	997	Survivors of childhood cancer (medulloblastoma)	0–21	389 (39)	Non-Hispanic White, Non-Hispanic Black, Hispanic, Other
Singh-Manoux et al., 2018	United Kingdom	1985–2002	23.7 years (mean)	Medical records, clinical examination, laboratory values, self-report (questionnaire)	8,270	General population	50	2,720 (33)	White, Non-White
Tomasdottir et al., 2016	Norway	1995–2008	11.0 years (mean)	Self-report (questionnaire), clinical evaluation, laboratory values	20,365	General population	20–59	10,938 (54)	Not specified
Ungprasert et al., 2017	USA	1976–2013	Cases: 12.9 years (median), Comparators: 15.6 years (median)	Medical records	690	Persons diagnosed with sarcoidosis	Cases: 45.6 (mean), Comparators: 45.4 (mean)	345 (50)	Caucasian, African-American, Asian, Native, American, Other
van den Akker et al., 1998	Netherlands	1993–1994	1.0 years	Medical records	60,857	General population	All ages	31,227 (51)	Not specified
Wikström et al., 2015	Finland	1982–2002	10 years	Self-reporting (questionnaire), clinical evaluations, laboratory values	32,972	General population	25–64	17,068 (52)	Not specified
Wilson-Genderson et al., 2017	USA	2006–2014	8 years	Self-report (questionnaire)	3,396	General population	50–74	2,080 (61)	White, African-American
Xu et al., 2018	Australia	1996–2016	20 years	Self-report (survey)	11,941	Women	45–50	11,941 (100)	Not specified
Xu et al., 2019	Australia	1996–2016	20 years	Self-report (survey)	7,357	Women	45–50	7,357 (100)	Not specified
Xu et al., 2020	Australia	2010–2016	6 years	Self-report (survey)	5,107	Women reporting premature ANM	45–50	5,107 (100)	Not specified
Xu, Mishra & Jones, 2019	Australia	1996–2016	20 years	Self-report (survey)	6,398	Women	45–50	6,398 (100)	Not specified

ANM, age at natural menopause; ART, antiretroviral therapy; HIV, human immunodeficiency virus; IR, incidence rate.

^a As provided by study authors as either mean or median years, or person-years. Group-specific mean (or median) follow-up periods are included for studies which did not report an overall mean or median follow-up period.

^b Without multimorbidity at baseline, as defined by study author(s).

^c Age at baseline; reported as range or mean or median if an exact range was not reported.

^d Ethnicity is reported using terminology directly reported by study authors. Elaboration of ethnicities included in groups is provided where reported.

^e This age refers to the age of participants at baseline among all study participants irrespective of multimorbidity status as the age specific to participants without multimorbidity at baseline was not provided by authors.

^f This proportion of females refers to the proportion at baseline among all study participants irrespective of multimorbidity status as the proportion of females specific to participants without multimorbidity at baseline was not provided by authors.

Table 2 reports characteristics of the five studies reporting patterns in accumulation of chronic conditions resulting in multimorbidity. Similar to studies reporting incidence of multimorbidity, accumulation studies were heterogeneous across all descriptive variables, including geographical location of study; data collection and follow-up period; sample population and size; and demographics. The majority of studies reported either national or local patterns in accumulation of chronic conditions in HICs.^{25,107,111,118} Most accumulation studies sampled general populations and sample sizes ranged from 9,160 and approximately 5 million. Comparable to studies reporting incidence of multimorbidity, study population ages ranged across the lifespan with most studying older adults only. One study reported race and ethnicity,¹⁰⁷ and data were most commonly sourced from medical records.

Table 2.

Baseline characteristics of studies and participants reporting accumulation of chronic conditions (n = 5).

Study, year of publication	Country	Data collection period	Follow-up period^a	Data source	Sample size	Population	Age, years (range)^b	Female, n (%)	Ethnicity
Ashworth et al., 2019	United Kingdom	2004–2018	Not specified	Medical records	332,353	Primary care	≥18	164,487 (49)	Black, South Asian, Mixed, Other, Unknown
Freisling et al., 2020	Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom	1992–2010	11.0 years (mean)	Self-report (questionnaire), medical records, health insurance records	291,778	General population	43–58 (median)	186,564 (64)	Not specified
Haug et al., 2020	Austria	2003–2014	12.0 years	Medical records	5,112,811	General population	All ages	Not specified	Not specified
Jørgensen et al., 2020	Denmark	1994–2016	Not specified	Medical records	73,213	Persons with AD and VaD	AD: 80.32 (mean),VaD: 79.12 (mean)	44,786 (61)	Not specified
Strauss et al., 2014	United Kingdom	2003–2005	3.0 years	Medical records	9,160	Primary care	50–75	5,166 (56)	Not specified

AD: Alzheimer’s disease; VaD: Vascular dementia.

^a As provided by study authors as either mean or median years. Group-specific mean (or median) follow-up periods are included for studies which did not report an overall mean or median follow-up period.

^b At baseline.

Incidence of multimorbidity

The incidence of multimorbidity for the 32 incidence studies are reported in Table 3 .

Table 3.

Incidence of multimorbidity by study (n = 32).

Study, year of publication	Group	Incidence	Adjustment
Studies reporting incidence rates (n = 14)
Aminisani et al., 2019^a	Overall	68.5 per 1,000 person-years	Unadjusted
Bjur et al., 2019^a	1999 cohort	2.56 per 1,000 person-years	Adjusted for age, sex, and ethnicity
Bjur et al., 2019^a	2004 cohort	3.00 per 1,000 person-years	Adjusted for age, sex, and ethnicity
Bjur et al., 2019^a	2009 cohort	3.35 per 1,000 person-years	Adjusted for age, sex, and ethnicity
Castilho et al., 2019^a	Multiple	Varied between 11.87–14.97 per 1,000 person-years by age and length of follow-up period (1 to 11 years from study entry)	Unadjusted
Castilho et al., 2020^a	Multiple	Varied between 24.0–51.5 per 1,000 person-years by age group (30 to 70+ years)	Unadjusted
Chan et al., 2019^a	Multiple	Varied between 17.4–160.9 per 1,000 person-years by age group (45 to 85+ years)	Unadjusted
Dhalwani et al., 2016^a	Overall	59 per 1,000 person-years	Unadjusted
Dugravot et al., 2020^a	Overall	13.87 per 1,000 person-years	Unadjusted
Freisling et al., 2020^a	Cancer to multimorbidity	13 per 1,000 person-years	Unadjusted
Freisling et al., 2020^a	CVD to multimorbidity	31.3 per 1,000 person-years	Unadjusted
Freisling et al., 2020^a	T2D to multimorbidity	25.0 per 1,000 person-years	Unadjusted
Hussin et al., 2019^a	Zero conditions at baseline	137 per 1,000 person-years	Unadjusted
Hussin et al., 2019^a	One condition at baseline	342 per 1,000 person-years	Unadjusted
Kivimäki et al., 2017^a	Overall	1.26 per 1,000 person-years (cardiometabolic multimorbidity)	Unadjusted
Lau et al., 2019^a	At 18 months follow-up	237 per 1,000 person-years	Unadjusted
Lau et al., 2019^a	At 36 months follow-up	215 per 1,000 person-years	Unadjusted
Licher et al., 2019^a	Overall	20.7 per 1,000 person-years	Unadjusted
Melis et al., 2014^a	Zero conditions at baseline	126 per 1,000 person-years	Unadjusted
Melis et al., 2014^a	One condition at baseline	329 per 1,000 person- years	Unadjusted
St Sauver et al., 2015^a	Women	38.8 per 1,000 person-years	Adjusted by age and sex to the total US 2010 Decennial Census
St Sauver et al., 2015^a	Men	35.5 per 1,000 person-years	Adjusted by age and sex to the total US 2010 Decennial Census
Studies reporting cumulative incidence (n = 18)
Demirchyan et al., 2013^a	Overall	61.0% over 22 years	Unadjusted
Guaraldi et al., 2015	Overall	9.7% over 3 years	Unadjusted
Hohmann et al., 2019^a	Multiple	Varied between 0.3% and 5.4% by sex, birth cohort, length of follow-up period, and age group (4 to 20 years) (respiratory multimorbidity)	Unadjusted
Marengoni et al., 2018^a	Control with zero chronic conditions at baseline	16.5% over 2 years	Unadjusted
Marengoni et al., 2018^a	Control with one chronic condition at baseline	44% over 2 years	Unadjusted
Marengoni et al., 2018^a	Intervention with zero chronic conditions at baseline	10.8% over 2 years	Unadjusted
Studies reporting cumulative incidence (n = 18)
Marengoni et al., 2018^a	Intervention with one chronic condition at baseline	33.2% over 2 years	Unadjusted
Mounce et al., 2018^a	Zero conditions at baseline	25.5% over 10.1 years	Unadjusted
Mounce et al., 2018^a	One condition at baseline	65.3% over 10.1 years	Unadjusted
Niedzwiedz et al., 2019	Overall	30.3% over 6 years	Unadjusted
Ryan et al., 2018^a	Overall	30.4% over 2 years	Unadjusted
Salloum et al., 2019^a	Cohort diagnosed with medulloblastoma in 1970s	12.2% over 15 years	Unadjusted
Salloum et al., 2019^a	Cohort diagnosed with medulloblastoma in 1980s	19.6% over 15 years	Unadjusted
Salloum et al., 2019^a	Cohort diagnosed with medulloblastoma in 1990s	23.9% over 15 years	Unadjusted
Singh-Manoux et al., 2018^a	Overall	6.18% over 23.7 years (cardiometabolic multimorbidity)	Unadjusted
Tomasdottir et al., 2016^a	Overall	30.8% over 11 years	Unadjusted
Ungprasert et al., 2017^a	Referent (non-sarcoidosis participants)	31.7% over 15.6 years (median)	Unadjusted
Ungprasert et al., 2017^a	Participants with sarcoidosis	45.5% over 12.9 years (median)	Unadjusted
van den Akker et al., 1998^a	Overall	1.3% over 1 year	Unadjusted
Wikström et al., 2015	Women with zero conditions at baseline	1% over 10 years	Unadjusted
Wikström et al., 2015	Men with zero conditions at baseline	2% over 10 years	Unadjusted
Wikström et al., 2015	Women with DM at baseline	22.6% over 10 years	Unadjusted
Wikström et al., 2015	Men with DM at baseline	30.8% over 10 years	Unadjusted
Wikström et al., 2015	Women with CVD at baseline	24% over 10 years	Unadjusted
Wikström et al., 2015	Men with CVD at baseline	23.3% over 10 years	Unadjusted
Wilson-Genderson et al., 2017^a	Overall	41.6% over 12 years (by T4)	Unadjusted
Xu et al., 2018^a	Overall	16.8% over 20 years	Unadjusted
Xu et al., 2019^a	Overall	60.4% over 20 years	Unadjusted
Xu et al., 2020^a	Multiple	Varied between 35.9% and 66.7% by age group at natural menopause (≤40 to ≥54 years)	Unadjusted
Xu, Mishra & Jones, 2019^a	Control (women without DEP)	52.6% over 18 years	Unadjusted
Xu, Mishra & Jones, 2019^a	Women with DEP	76.8% over 18 years	Unadjusted

ANM, age at natural menopause; BMI, body mass index; CVD, cardiovascular disease; DEP, depression; DM, diabetes mellitus; HIV, human immunodeficiency virus; T2D, type II diabetes.

^a Additional incidence rate(s) and/or cumulative incidence available in study text.

Among the 14 studies reporting IRs, rates were highly heterogeneous. Only five of the 14 studies reported an overall IR in addition to group-specific rates.^{109,121,123,126,132} Across studies reporting incidence, the median (unadjusted) incidence rate was 30.7 per 1,000 person-years (IQR 39.5 per 1,000 person-years) and the median (unadjusted) cumulative incidence was 2.8% (IQR 28.7%). Incidence rates ranged from 1.26 to 342 per 1,000 person-years. Of all incidence studies, two adjusted incidence for age, sex, and/or ethnicity.^129,130 IRs across the lifespan increased with age, with studies of middle-aged to older participants (50+ years of age) reporting higher IRs than those consisting of younger and adult populations (0–40 years of age). Most studies did not stratify IRs by sex, with only one reporting IRs among male and female participants separately¹³⁰; this study reported a higher IR among women than in men. Of the 11 studies reporting race and/or ethnicity, five reported incidence rate(s) stratified by race and/or ethnicity,^{109,112,123,129,132} one adjusted incidence rates for race and/or ethnicity,¹³⁶ and two presented both adjusted overall and stratified incidence rate(s) by race and/or ethnicity.^129,130 Two studies consisting solely of South and East Asian ethnicities (Malay, Chinese, and Indian)^110,112 reported higher IRs than the remaining studies reporting IRs in White, Non-White, Black/African-American, Hispanic, and Māori populations.

Cumulative incidences of multimorbidity are presented in Table 3. Of the 18 studies reporting cumulative incidence, 10 studies reported overall unadjusted cumulative incidence ranging from 1.3% to 61.0%. Group-specific values ranged between 0% of participants developing multimorbidity (expressed in a European study as development of four chronic conditions over 2-year follow-up)¹¹⁶ and 76.8% of participants developing multimorbidity (defined in an Australian study of women as development of two or more chronic conditions over 20-year follow-up).¹³⁹ Amongst five studies of specific patient populations, three had higher cumulative incidence^108,137,138 compared to those conducted in general populations.

Across studies reporting either incidence rate or cumulative incidence, studies of older (45+ years of age) populations reported higher cumulative incidence than those which included younger population (<21 years of age).^119,133 Additionally, in studies which presented incidence stratified by baseline disease counts, persons with one chronic condition at baseline had higher incidence of multimorbidity by the end of study follow-up, compared to those with zero at baseline.^{110,113,116,128,134,137,139} With the exception of one,¹¹² studies including nine or more chronic conditions in their definition of multimorbidity reported higher incidence than those including fewer conditions.

Patterns in accumulation of chronic conditions

The five articles that studied the accumulation of chronic conditions varied in the methods used to determine patterns, format of reporting, and in the component chronic conditions making up multimorbidity (Table 4). Four studies reported overall pattern(s) in accumulation^{25,107,111,118} and, of these, only one reported additional patterns by demographic subgroups¹⁰⁷ and one reported patterns in accumulation by starting condition among participants.¹¹⁷ Three studies characterized the order of component chronic conditions as trajectories,^25,111,118 one as transitions,¹¹⁷ and one as pathways.¹⁰⁷ All but two studies^25,107 reported patterns in accumulation of chronic conditions in populations of individuals with specific underlying diseases.

Table 4.

Patterns in accumulation of component chronic conditions in multimorbidity and methods used to ascertain patterns (n = 5).

Study, year of publication	Patterns in accumulation
Ashworth et al., 2019	Overall: Diabetes and depression were the most common starting conditions. Chronic pain was more common as a second or third acquired condition. Age: Under 65 years, the most common starting condition was depression. In 65+ years, the most common starting conditions were diabetes and CHD. Deprivation: In most deprived, the most common starting conditions were diabetes and depression. In least deprived, the most common starting conditions were diabetes and CHD.Ethnicity: Among Black participants, diabetes was the most common starting condition; serious mental illness and depression were also common starting conditions. Among White participants, depression was the most common starting condition.
Freisling et al., 2020	Cancer: Transitions to multimorbidity through acquiring CVD or T2D at 6.5 events/1,000 person-years.CVD: Transition to multimorbidity through acquiring cancer at 16.6 events/1,000 person-years and through acquiring T2D at 14.7 events/1,000 person-years. T2D: Transition to multimorbidity through acquiring cancer at 14.3 events per 1,000 person-years and through acquiring CVD at 10.7 events/1,000 person-years.
Haug et al., 2020	Overall: 132 clusters of chronic conditions (ICD-10 diagnoses) identified with cluster 0 (no known prior diagnoses) a beginning healthy state for participants. Reduced disease trajectory was defined by accumulation of additional clusters over time, with time period where no new clusters accumulated were removed. Cerebrovascular disease: More than 50% followed reduced trajectories of length greater than two. Most frequent reduced trajectory of length 3 is (0, 114, 123); patients from healthy cluster 0 move to cluster 114 (hypertensive diseases I10–I15 and heart diseases I30–I52) to cluster 123 where cerebrovascular diseases become included (cluster 123). Malignant neoplasms: More than 50% only visit two different clusters, and 44% of those had reduced trajectory (0, 55), healthy cluster to a cancer cluster. Most frequent reduced trajectory of length 3, was 0, 55, 109, where patients acquire hypertensive diseases (I10–I15) after cancer. Mood disorders: 9.5% ended their trajectory in cluster 71 where, additional to mood disorders, they were diagnosed with mental and behavioral disorders due to psychoactive substance use (F10–F19).
Jørgensen et al., 2020	Overall: For both types of dementia, many trajectories contained F03 “Unspecified dementia” and subsequently F00 “Dementia in Alzheimer disease.” E10 “Type I diabetes mellitus” and E11 “Type II diabetes mellitus” are common paths toward a dementia diagnosis, as are cardiovascular diseases like I10 “Hypertension,” I20 “Angina pectoris,” and I50 “Heart failure.” Alzheimer’s Disease: 50 significant directional trajectories consisting of three consecutive diseases. Vascular Dementia: 215 significant directional trajectories consisting of three consecutive diseases.
Strauss et al., 2014	Overall: Five trajectories identified: 1) those with no recorded chronic problems; 2) those who developed first chronic morbidity over 3 years; 3) developing multimorbidity group characterized by progressing from zero or one chronic morbidity at the first period to two or three by the sixth period; 4) those with increasing number of chronic morbidities; and 5) multi-chronic group with many chronic morbidities. The most common trajectories started with hypertension in the first period and developed osteoarthritis, diabetes mellitus, and/or pure hypercholesterolemia over the six periods.

CHD: coronary heart disease; CVD: Cardiovascular disease; ICD-10: International Classification of Diseases, version 10.

As reported by Ashworth et al.,¹⁰⁷ starting conditions varied by age, social deprivation, and ethnicity. For example, depression was more common as a starting condition in individuals under 65 years of age, while diabetes and CHD were more common in those 65+ years of age.¹⁰⁷ Four studies reported hypertensive and heart diseases as among the common starting conditions resulting in later multimorbidity^{25,111,117,118} and two reported diabetes as the most common starting condition.^107,111 Second and third conditions contributing to multimorbidity were highly variable amongst reported patterns; two studies indicated cerebrovascular diseases and mental health illness (i.e. mood disorders) as common second conditions resulting in multimorbidity status.^111,118 This is in contrast to one study reporting a mental health illness (depression) as a common overall starting condition.¹⁰⁷ Additional second- and third-component conditions reported include chronic pain, osteoarthritis, cancer, diabetes, and hypercholesterolemia.^25,107,117

Methods in determining patterns in accumulation of chronic conditions

There were diverse methods used by the five studies to determine and report the accumulation of component chronic conditions leading to multimorbidity; despite this diversity, each study reported their results diagrammatically.

Ashworth et al.¹⁰⁷ employed alluvial plots,¹⁴⁰ whereby the chronic conditions in the accumulation sequence are assigned to vertical axes. Bar heights of the vertical axes were used to represent the number of persons with a particular chronic condition, and the widths of “streams” joining bars were used to represent the number of persons in each adjoining pair of chronic conditions. Freisling et al.¹¹⁷ identified chronic conditions and calculated hazard ratios for movement from one starting condition to another, reported as the number of cases per 1,000 person-years. Separate pathway diagrams representing acquisition sequencing of three conditions were presented.

Haug et al.¹¹⁸ employed machine learning to develop trajectories for risk of cardiovascular mortality based on divisive cluster analysis, in which all persons started in the same cluster and were algorithmically divided into different clusters according to the chronic conditions acquired over time. The study presented cluster trajectories as a multilayer network diagram.

Jørgensen et al.¹¹¹ examined pre-dementia temporal accumulation of multimorbidity for persons with Alzheimer’s disease and vascular dementia. Disease pairs were examined to determine which condition came first. The relative risk for acquiring the second condition for those with dementia compared to matched controls, was calculated. In addition to relative risks, the study presented temporal disease trajectory networks of diagnoses for persons with dementia, where each condition is a node joined by lines that indicate accumulation pathways.

Strauss et al.²⁵ conducted a latent class growth analysis to identify distinct multimorbidity trajectories. The analysis began with a one-cluster model (all persons having the same trajectory). The number of clusters was increased until most heterogeneity was explained. Quadratic growth curves were applied, and persons were assigned to a cluster in which their posterior probability of membership was highest. The trajectories of numbers of accumulating conditions were presented graphically using latent class growth trajectories.

Discussion

This systematic review contributes to a growing body of literature concerning the epidemiology of multimorbidity by providing a comprehensive, qualitative analysis of multimorbidity incidence and patterns in the accumulation of chronic conditions. The purpose of most included studies was to determine the incidence of multimorbidity and/or accumulation of component chronic conditions leading to multimorbidity. However, nine studies had other primary objectives and were able to opportunistically examine incidence.^{111,112,116,119,122,123,134,136,141}

Of the 32 studies reporting incidence, five studies reported overall IRs ranging from 1.26 to 68.5 per 1,000 person-years, and 10 studies reported overall cumulative incidence ranging from 1.3% to 61.0%. The wide variation among incidence estimates in these 15 studies may be attributed to differences in: study populations being examined, with some sampling general populations and others sampling patient populations with specific baseline conditions; age and race or ethnicities of study participants; follow-up duration; as well as a lack of uniformity in the criteria that were used to define multimorbidity. The remaining 17 incidence studies reported incidence stratified by sociodemographic and medical factors. This helps elucidate factors impacting multimorbidity; however, it would facilitate comparisons across studies if authors report, where possible, overall rates adjusted for factors known to be associated with multimorbidity, including (at minimum) age, sex/gender, and number of baseline conditions.^58,142 Only two studies in this review adjusted overall incidence for age and sex.^129,130

The findings from this review regarding the relationship between multimorbidity and the number of baseline chronic condition(s), age, and sex generally aligned with previous literature. In studies which presented incidence stratified by baseline disease counts, persons with one chronic condition at baseline had higher incidence of multimorbidity later in life, compared to those with zero at baseline. This may be due in part to underlying genetic mechanisms of chronic diseases¹⁴³; systemic health impacts of chronic conditions in diagnosed individuals¹⁴⁴; and/or persons with a baseline chronic condition being more likely to seek medical help,¹⁴⁵ and therefore more likely to be diagnosed with other illnesses unrelated to the initial illness. Both incidence rates and cumulative incidence were higher in older populations, consistent with the well-documented relationship between age and multimorbidity.^146–148 Amongst studies reporting incidence by sex, IRs and cumulative incidence were higher for women than men. This relationship between sex and multimorbidity is consistent with literature indicating that women may be more likely to be diagnosed with chronic conditions because they are more likely to seek medical help^149–152 and have higher life expectancies than men.^142,153,154

Of all identified studies reporting patterns in the accumulation of multimorbidity’s component chronic conditions, only five studies met our selection criteria. This review indicates distinct patterns in accumulation of chronic conditions, as reported by studies elucidating cardiovascular and metabolic conditions amongst the most common starting conditions, and cerebrovascular and mental illnesses as common second conditions resulting in multimorbidity. Together, cardiometabolic conditions including stroke, heart disease, and diabetes, contribute to leading causes of morbidity, mortality, lower quality of life, and health resource use globally.^{117,155–157} Understanding disease trajectories as discussed in this review may help clinicians identify persons at greater risk of developing such conditions and better understand their prognosis in order to effectively prevent and manage this set of diseases. Depression was noted as a common starting condition in persons below 65 years of age, which may be attributed in part to cultural trends in digital and communication media, sleep deprivation, and social deprivation in younger persons, contributing to rising rates of mood disorders and suicidal thoughts and behaviors since the mid-2000s, factors which may have a greater impact on younger persons compared to older generations.^107,158 This result was found only in one study in accumulation, demonstrating the need for future research to confirm these findings in other populations. There is significant diversity in the definition of “patterns” in multimorbidity research, with some studies employing a temporal component^{25,107,111,117,118} and others using the term almost synonymously with patient clusters.⁶³ Methods used to discern accumulation were highly heterogeneous and showed novel applications of advanced statistical techniques. A common feature of the five articles was the use of diagrams to demonstrate temporal relationships. Ongoing innovation in this area bodes well for future research that examines the accumulation of component chronic conditions in multimorbidity and may inform preventative efforts.

We identified articles that used the term accumulation differently than we had initially set out in our objectives, which was to examine the order of chronic condition accumulation leading to an individual having multimorbidity. As such, we excluded studies that measured speed of accumulation of chronic conditions⁴⁶ and those that measured accumulation as most commonly occurring incident dyads and triads of chronic conditions without consideration for order or disease onset.¹³⁰ However, this diversity in the definition of accumulation can add to the richness of understanding multimorbidity incidence, and therefore an in-depth examination taking into account all aspects and forms of accumulation reported across the literature is warranted.

Our review found limitations in the included studies with respect to age, sex and gender, and race and ethnicity. The study of multimorbidity is heavily focused toward adult and elderly populations^159–161; however, incidence of multimorbidity amongst children and adolescents who have chronic conditions warrants more attention given their increased risk of developing additional diseases later in life.^162,163 Additionally, most studies reported patterns by chronic conditions and only one reported patterns by demographic factors, such as age.

All studies in our review were not explicit in their definitions of sex and gender. Such studies are failing to define sex and gender as non-binary variables when studying the health of populations.^164,165 Among studies that reported race and/or ethnicity, data were collected from different sources ranging from medical records to self-report. The COVID-19 pandemic underscored the importance of calculating race and ethnic-specific incidence of multimorbidity.^166,167 Routine collection of these data is a necessary step to understanding the role of race and/or ethnicity in multimorbidity incidence.

The findings from our systematic review demonstrate heterogeneity across studies with respect to incidence of multimorbidity and with respect to the order in which component chronic conditions that lead to multimorbidity were accumulated. This is consistent with reviews reporting the prevalence of multimorbidity^26,28 for similar reasons as have been found in these prevalence studies. The heterogeneity across articles may be due in part to diverse study objectives, study designs, and operational definitions for multimorbidity across the included studies. More specifically, the widely varying number and selection of chronic conditions contributing to the definition of multimorbidity poses significant challenges to the comparison of findings among studies. For example, there is well-established evidence that hypertension is a precursor to multimorbidity in adult populations^168,169; however, some studies did not include hypertension in their definition of multimorbidity. This finding may be the result of specific studies’ consideration of hypertension as a risk factor and not as a disease.¹⁷⁰

While study specificity in design or operational definition of multimorbidity may allow for more targeted study of multimorbidity within a given population, it contributes to the complexity of comparing incidence and accumulation of multimorbidity across studies. Given the heterogeneity among incidence studies, authors should be transparent in reporting results. At minimum, authors should explicitly state their definition of multimorbidity, clearly indicating the number of co-occurring conditions required to define multimorbidity, and the number and selection of chronic conditions included in their list of component chronic conditions. Additionally, where the available data permit, studies are encouraged to limit defining conditions of multimorbidity to five relevant chronic conditions, including those with well-established links to increased risk of multimorbidity development, including cardiovascular diseases,^171,172 hypertension,^168,170 and diabetes.^173,174

This systematic review studied the incidence of multimorbidity and patterns in accumulation of chronic conditions across the lifespan, including children. Our consideration of all age groups is a strength of this review in light of evidence demonstrating the onset of a number of morbidities at younger ages; possibilities for illnesses to transition to chronic status; and the value of early identification in timely intervention and mitigating disease progression.¹²⁷ In addition, incidence rates were stratified by reporting format (IR or cumulative incidence) for more accurate comparison among study findings. This review was conducted in accordance with PROSPERO guidelines by two reviewers, with title and abstract screening, full-text review, data extraction, and quality assessment of studies completed independently. Included studies were mostly of high quality in accordance with the NOS, AHRQ, and Cochrane RoB criteria.

An inherent limitation amongst all systematic reviews is the omission of potentially relevant articles. Due to our inclusion criteria requiring articles to be of either English or French language, 122 non-English/French studies were excluded early in the review process without consideration for inclusion, some of which may have been relevant to our study. In addition, studies of low quality in reporting were not excluded to ensure the full spectrum of literature in multimorbidity was included in this review. This may have impacted the accuracy of these studies’ estimates. For example, studies which scored low on representativeness may produce estimates that do not represent the true estimates for their target population; however, it is not possible to discern whether such estimates are inflated or deflated. Similarly, studies which scored low on reporting outcome assessment may have estimates lower than actual because they did not adequately capture every occurrence of multimorbidity. Finally, while studies in this review reported on chronic conditions or non-communicable diseases, three studies also included a small count of acute conditions in their definitions and four did not specify a definition of multimorbidity (Supplementary Table S6). Despite the lack of explicit definition of multimorbidity in these studies, we were confident in including their work given reference to 2+ conditions in prose and/or tables.

Conclusion

Establishing the incidence of multimorbidity is a critical step in understanding the etiology and informing prevention of multimorbidity in general and specific patient populations across the lifespan. This systematic review of 36 studies presents that nearly 31 per 1,000 person-years (IQR 39.5 per 1,000 person-years) and 3% (IQR 28.7%) of the studied populations included in this review are affected by multimorbidity, and that component chronic conditions contributing to the development of multimorbidity are highly heterogenous. We recommend that researchers be transparent in reporting the components of their operational definitions of multimorbidity, and that patterns in multimorbidity be differentiated by age group and sex and/or gender to allow more specific analyses of the incidence of multimorbidity, and its implication for health care and health systems. Our findings support the importance of work underway to determine a standardized operational definition of multimorbidity.¹⁷⁵ These practices will allow for more accurate comparison and estimation of the incidence and progression of multimorbidity, and subsequently, more effective disease management and preventative interventions across all stages of life.

Supplemental material

Supplemental Material, sj-docx-1-cob-10.1177_26335565211032880 - The incidence of multimorbidity and patterns in accumulation of chronic conditions: A systematic review

Supplemental Material, sj-docx-1-cob-10.1177_26335565211032880 for The incidence of multimorbidity and patterns in accumulation of chronic conditions: A systematic review by Prtha Kudesia, Banafsheh Salimarouny, Meagan Stanley, Martin Fortin, Moira Stewart, Amanda Terry and Bridget L Ryan in Journal of Comorbidity

Supplemental material

Supplemental Material, sj-docx-2-cob-10.1177_26335565211032880 - The incidence of multimorbidity and patterns in accumulation of chronic conditions: A systematic review

Supplemental Material, sj-docx-2-cob-10.1177_26335565211032880 for The incidence of multimorbidity and patterns in accumulation of chronic conditions: A systematic review by Prtha Kudesia, Banafsheh Salimarouny, Meagan Stanley, Martin Fortin, Moira Stewart, Amanda Terry and Bridget L Ryan in Journal of Comorbidity

Supplemental material

Supplemental Material, sj-pdf-1-cob-10.1177_26335565211032880 - The incidence of multimorbidity and patterns in accumulation of chronic conditions: A systematic review

Supplemental Material, sj-pdf-1-cob-10.1177_26335565211032880 for The incidence of multimorbidity and patterns in accumulation of chronic conditions: A systematic review by Prtha Kudesia, Banafsheh Salimarouny, Meagan Stanley, Martin Fortin, Moira Stewart, Amanda Terry and Bridget L Ryan in Journal of Comorbidity

Footnotes

Authors’ note

Banafsheh Salimarouny and Prtha Kudesia are joint first authors.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

Prtha Kudesia

Martin Fortin

Bridget L Ryan

Supplemental material

Supplemental material for this article is available online.

References

Battegay

. Multimorbidity is a game changer. Swiss Med Wkly. https://doi.emh.ch/smw.2019.20131 (2019, accessed 12 December 2020).

Pearson-Stuttard

Ezzati

Gregg

. Multimorbidity—a defining challenge for health systems. Lancet Public Health 2019; 4(12): e599–e600.

Boyd

Fortin

. Future of multimorbidity research: how should understanding of multimorbidity inform health system design? Public Health Rev 2010; 32(2): 451–474.

Canadian Institute for Health Information. Seniors and the health care system: what is the impact of multiple chronic conditions. Toronto: Canadian Institute for Health Information, 2011.

Ryan

Allen

Zwarenstein

, et al. Multimorbidity and mortality in Ontario, Canada: a population-based retrospective cohort study. J Comorb 2020; 10: 1–10.

Lund Jensen

Pedersen

Vestergaard

, et al. The impact of socioeconomic status and multimorbidity on mortality: a population-based cohort study. Clin Epidemiol 2017; 9: 279–289.

Hanlon

Nicholl

Jani

, et al. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank participants. Lancet Public Health 2018; 3(7): e323–e332.

Randall

Lujic

Havard

, et al. Multimorbidity among aboriginal people in new south wales contributes significantly to their higher mortality. Med J Australia 2018; 209(1): 19–23.

Singh

Patel

Biswas

, et al. Multimorbidity in South Asian adults: prevalence, risk factors and mortality. J Public Health (Oxf) 2019; 41(1): 80–89.

10.

Stanley

Semper

Millar

, et al. Epidemiology of multimorbidity in New Zealand: a cross-sectional study using national-level hospital and pharmaceutical data. BMJ Open 2018; 8(5): e021689.

11.

Willadsen

Siersma

Nicolaisdóttir

, et al. Multimorbidity and mortality: a 15-year longitudinal registry-based nationwide Danish population study. J Comorb 2018; 8(1): 2235042X18804063.

12.

Jani

Hanlon

Nicholl

, et al. Relationship between multimorbidity, demographic factors and mortality: findings from the UK Biobank cohort. BMC Med 2019; 17(1): 74.

13.

DuGoff

Canudas-Romo

Buttorff

, et al. Multiple chronic conditions and life expectancy: a life table analysis. Med Care 2014; 52(8): 688–694.

14.

Nunes

Flores

Mielke

, et al. Multimorbidity and mortality in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr 2016; 67: 130–138.

15.

Leme DE da

Thomaz

Borim

FSA

, et al. Survival of elderly outpatients: effects of frailty, multimorbidity and disability. Cien Saude Colet 2019; 24(1): 137–146.

16.

Ibarra-Castillo

Guisado-Clavero

Violan-Fors

, et al. Survival in relation to multimorbidity patterns in older adults in primary care in Barcelona, Spain (2010-2014): a longitudinal study based on electronic health records. J Epidemiol Commun Health 2018; 72(3): 185–192.

17.

Nguyen

Odden

, et al. Multimorbidity patterns, frailty, and survival in community-dwelling older adults. J Gerontol A Biol Sci Med Sci 2019; 74(8): 1265–1270.

18.

Rivera-Almaraz

Manrique-Espinoza

Ávila-Funes

, et al. Disability, quality of life and all-cause mortality in older Mexican adults: association with multimorbidity and frailty. BMC Geriatr 2018; 18(1): 236.

19.

Schäfer

Kaduszkiewicz

Nguyen

, et al. Multimorbidity patterns and 5-year overall mortality: Results from a claims data-based observational study. J Comorb 2018; 8(1): 2235042X18816588.

20.

Wei

Kabeto

Galecki

, et al. Physical functioning decline and mortality in older adults with multimorbidity: joint modeling of longitudinal and survival data. J Gerontol A Biol Sci Med Sci 2019; 74(2): 226–232.

21.

Salisbury

Johnson

Purdy

, et al. Epidemiology and impact of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract 2011; 61(582): e12–e21.

22.

Huntley

Johnson

Purdy

, et al. Measures of multimorbidity and morbidity burden for use in primary care and community settings: a systematic review and guide. Ann Fam Med 2012; 10(2): 134–141.

23.

Muggah

Graves

Bennett

, et al. The impact of multiple chronic diseases on ambulatory care use; a population based study in Ontario, Canada. BMC Health Serv Res 2012; 12(1): 452.

24.

Rosella

Fitzpatrick

Wodchis

, et al. High-cost health care users in Ontario, Canada: demographic, socio-economic, and health status characteristics. BMC Health Serv Res 2014; 14(1): 532.

25.

Strauss

Jones

Kadam

, et al. Distinct trajectories of multimorbidity in primary care were identified using latent class growth analysis. J Clin Epidemiol 2014; 67(10): 1163–1171.

26.

Fortin

Stewart

Poitras

M-E

, et al. A systematic review of prevalence studies on multimorbidity: toward a more uniform methodology. Ann Fam Med 2012; 10(2): 142–151.

27.

Smith

Soubhi

Fortin

, et al. Managing patients with multimorbidity: systematic review of interventions in primary care and community settings. BMJ 2012; 345: e5205.

28.

Nguyen

Manolova

Daskalopoulou

, et al. Prevalence of multimorbidity in community settings: a systematic review and meta-analysis of observational studies. J Comorb 2019; 9: 2235042X1987093.

29.

Moher

Liberati

Tetzlaff

, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8(5): 336–341.

30.

Lefebvre

Glanville

Briscoe

, et al. Chapter 4. Searching for and selecting studies. In: Higgins

Thomas

Chandler

Cumpston

Page

. (eds). Cochrane Handbook for Systematic Reviews of Interventions version 61. London: Cochrane, 2020. www.training.cochrane.org/handbook (updated September 2020, accessed 15 May 2020) .

31.

Wells

Shea

O’Connell

, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: University of Ottawa, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 23 January 2021).

32.

Higgins

JPT

Altman

Gotzsche

, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.

33.

Page

McKenzie

Bossuyt

, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med 2021; 18(3): e1003583.

34.

Hussain

Wark

Janicki

, et al. Multimorbidity in older people with intellectual disability. J Appl Res Intellect Disabil 2020; 33(6): 1234–1244.

35.

Lange-Maia

Karvonen-Gutierrez

Kazlauskaite

, et al. Impact of chronic medical condition development on longitudinal physical function from mid- to early late-life: the study of women’s health across the nation. Magaziner

, editor. J Gerontol Ser A 2020; 75(7): 1411–1417.

36.

Nguyen

Chua

K-C

Dregan

, et al. Factors associated with Multimorbidity patterns in older adults in England: findings from the English longitudinal study of aging (ELSA). J Aging Health 2020; 32(9): 1120–1132.

37.

Yao

S-S

Cao

G-Y

Han

, et al. Prevalence and patterns of multimorbidity in a nationally representative sample of older chinese: results from the china health and retirement longitudinal study. Newman

, editor. J Gerontol Ser A 2020; 75(10): 1974–1980.

38.

Timmermans

Hoogendijk

Broese van Groenou

, et al. Trends across 20 years in multiple indicators of functioning among older adults in the Netherlands. Eur J Public Health 2019; 29(6): 1096–1102.

39.

Gomis-Pastor

Roig Mingell

Mirabet Perez

, et al. Multimorbidity and medication complexity: New challenges in heart transplantation. Clin Transplant 2019; 33(10): e13682.

40.

Juul-Larsen

Christensen

Bandholm

, et al. Patterns of multimorbidity and differences in healthcare utilization and complexity among acutely hospitalized medical patients (≥65 years)—a latent class approach. Clin Epidemiol 2020; 12: 245–259.

41.

Kuan

Denaxas

Gonzalez-Izquierdo

, et al. A chronological map of 308 physical and mental health conditions from 4 million individuals in the English National Health Service. Lan Digital Health 2019; 1(2): e63–e77.

42.

Calderón-Larrañaga

Vetrano

Welmer

A-K

, et al. Psychological correlates of multimorbidity and disability accumulation in older adults. Age Ageing 2019; 48(6): 789–796.

43.

Juul-Larsen

Andersen

Bandholm

, et al. Differences in function and recovery profiles between patterns of multimorbidity among older medical patients the first year after an acute admission—an exploratory latent class analysis. Arch Gerontol Geriatr 2020; 86: 103956.

44.

Kristensen

König

Hajek

. The longitudinal association of multimorbidity on loneliness and network size: findings from a population-based study. Int J Geriatr Psychiatry 2019; 34(10): 1490–1497.

45.

Gellert

von Berenberg

Zahn

, et al. Multimorbidity profiles in German centenarians: a latent class analysis of health insurance data. J Aging Health 2019; 31(4): 580–594.

46.

Dekhtyar

Vetrano

Marengoni

, et al. Association between speed of multimorbidity accumulation in old age and life experiences: a cohort study. Am J Epidemiol 2019; 188(9): 1627–1636.

47.

Hajek

Brettschneider

Eisele

, et al. Does transpersonal trust moderate the association between chronic conditions and general practitioner visits in the oldest old? Results of the AgeCoDe and AgeQualiDe study. Geriatr Gerontol Int 2019; 19(8): 705–710.

48.

Maciejewski

Hammill

. Measuring the burden of multimorbidity among Medicare beneficiaries via condition counts and cumulative duration. Health Serv Res 2019; 54(2): 484–491.

49.

Quiñones

Botoseneanu

Markwardt

, et al. Racial/ethnic differences in multimorbidity development and chronic disease accumulation for middle-aged adults. Ginsberg

, editor. PLoS One 2019; 14(6): e0218462.

50.

Lai

FTT

Guthrie

Wong

SYS

, et al. Sex-specific intergenerational trends in morbidity burden and multimorbidity status in Hong Kong community: an age-period-cohort analysis of repeated population surveys. BMJ Open 2019; 9(1): e023927.

51.

Tran

Norton

Conrad

, et al. Patterns and temporal trends of comorbidity among adult patients with incident cardiovascular disease in the UK between 2000 and 2014: a population-based cohort study. PLoS Med 2018; 15(3): e1002513.

52.

Schramm

Reuter

Grabenhenrich

, et al. What does lung function tell us about respiratory multimorbidity in childhood and early adulthood? Results from the MAS birth cohort study. Pediatr Allergy Immunol 2018; 29(5): 481–489.

53.

Sakib

Shooshtari

St John

, et al. The prevalence of multimorbidity and associations with lifestyle factors among middle-aged Canadians: an analysis of Canadian Longitudinal Study on Aging data. BMC Public Health 2019; 19(1): 243.

54.

Lebenbaum

Zaric

Thind

, et al. Trends in obesity and multimorbidity in Canada. Prevent Med 2018; 116: 173–179.

55.

Wang

J-H

Y-J

Tee

, et al. Medical comorbidity in alzheimer’s disease: a nested case-control study. J Alzheimers Dis 2018; 63(2): 773–781.

56.

Rosella

Kornas

Huang

, et al. Accumulation of chronic conditions at the time of death increased in Ontario from 1994 to 2013. Health Aff 2018; 37(3): 464–472.

57.

Humphreys

Jameson

Cooper

, et al. Early-life predictors of future multi-morbidity: results from the Hertfordshire Cohort. Age Ageing 2018; 47(3): 474–478.

58.

Calderón-Larrañaga

Santoni

Wang

, et al.

Rapidly developing multimorbidity and disability in older adults: does social background matter?

J Intern Med 2018; 283(5): 489–499.

59.

Kingston

Robinson

Booth

, et al. Projections of multi-morbidity in the older population in England to 2035: estimates from the Population Ageing and Care Simulation (PACSim) model. Age Ageing 2018; 47(3): 374–380.

60.

Wong

Gange

Moore

, et al. Multimorbidity among persons living with human immunodeficiency virus in the United States. Clin Infect Dis 2018; 66(8): 1230–1238.

61.

Chao

Chen

, et al. Multimorbidity and health-related quality of life among the community-dwelling elderly: a longitudinal study. Arch Gerontol Geriatr 2018; 74: 133–140.

62.

Canizares

Hogg-Johnson

Gignac

MAM

, et al. Increasing trajectories of multimorbidity over time: birth cohort differences and the role of changes in obesity and income. J Gerontol B Psychol Sci Soc Sci 2018; 73(7): 1303–1314.

63.

Alaeddini

Jaramillo

Faruqui

SHA

, et al. Mining major transitions of chronic conditions in patients with multiple chronic conditions. Methods Inf Med 2017; 56(05): 391–400.

64.

Rocca

Gazzuola Rocca

Smith

, et al. Cohort profile: the mayo clinic cohort study of oophorectomy and aging-2 (MOA-2) in Olmsted County, Minnesota (USA). BMJ Open 2017; 7(11): e018861.

65.

Admon

Winkelman

TNA

Moniz

, et al. Disparities in chronic conditions among women hospitalized for delivery in the United States, 2005-2014. Obstet Gynecol 2017; 130(6): 1319–1326.

66.

Katikireddi

Skivington

Leyland

, et al. The contribution of risk factors to socioeconomic inequalities in multimorbidity across the lifecourse: a longitudinal analysis of the Twenty-07 cohort. BMC Med 2017; 15(1): 152.

67.

Nagel

Jungert

Spinneker

, et al. The impact of multimorbidity on resting metabolic rate in community-dwelling women over a ten-year period: a cross-sectional and longitudinal study. J Nutr Health Aging 2017; 21(7): 781–786.

68.

Rocca

Gazzuola Rocca

Smith

, et al.

Bilateral oophorectomy and accelerated aging: cause or effect?

J Gerontol A Biol Sci Med Sci 2017; 72(9): 1213–1217.

69.

Bapat

Shapey

Toma

, et al. Chronic subdural haematomas: a single-centre experience developing an integrated care pathway. Br J Neurosurg 2017; 31(4): 434–438.

70.

Rocca

Gazzuola-Rocca

Smith

, et al. Accelerated Accumulation of multimorbidity after bilateral oophorectomy: a population-based cohort study. Mayo Clin Proc 2016; 91(11): 1577–1589.

71.

van Oostrom

Gijsen

Stirbu

, et al. Time trends in prevalence of chronic diseases and multimorbidity not only due to aging: data from general practices and health surveys. PLoS One 2016; 11(8): e0160264.

72.

Weimann

Dai

Oni

. A cross-sectional and spatial analysis of the prevalence of multimorbidity and its association with socioeconomic disadvantage in South Africa: a comparison between 2008 and 2012. Soc Sci Med 2016; 163: 144–156.

73.

Whitson

Johnson

Sloane

, et al. Identifying patterns of multimorbidity in older Americans: application of latent class analysis. J Am Geriatr Soc 2016; 64(8): 1668–1673.

74.

Jackson

Dobson

Tooth

, et al. Lifestyle and socioeconomic determinants of multimorbidity patterns among mid-aged women: a longitudinal study. Chamberlain

, editor. PLoS One 2016; 11(6): e0156804.

75.

Kenzik

Kent

Martin

, et al. Chronic condition clusters and functional impairment in older cancer survivors: a population-based study. J Cancer Surviv 2016; 10(6): 1096–1103.

76.

Fabbri

Zoli

, et al. Association between accelerated multimorbidity and age-related cognitive decline in older Baltimore longitudinal study of aging participants without Dementia. J Am Geriatr Soc 2016; 64(5): 965–972.

77.

Dhalwani

O’Donovan

Zaccardi

, et al. Long terms trends of multimorbidity and association with physical activity in older English population. Int J Behav Nutr Phys Act 2016; 13(1): 8.

78.

Pavela

Latham

. Childhood conditions and multimorbidity among older adults. GERONB 2016; 71(5): 889–901.

79.

Canizares

Gignac

Hogg-Johnson

, et al. Do baby boomers use more healthcare services than other generations? Longitudinal trajectories of physician service use across five birth cohorts. BMJ Open 2016; 6(9): e013276.

80.

Deckx

van den Akker

Metsemakers

, et al. Chronic diseases among older cancer survivors. J Cancer Epidemiol 2012; 2012: 1–7.

81.

Kim

Shin

Zurlo

. Sequential patterns of health conditions and financial outcomes in late life: evidence from the health and retirement study. Int J Aging Hum Dev 2015; 81(1–2): 54–82.

82.

Luo

Hendryx

Safford

, et al. Newly developed chronic conditions and changes in health-related quality of life in postmenopausal women. J Am Geriatr Soc 2015; 63(11): 2349–2357.

83.

Jackson

Dobson

Tooth

, et al. Body mass index and socioeconomic position are associated with 9-year trajectories of multimorbidity: a population-based study. Prev Med 2015; 81: 92–98.

84.

Jackson

Jones

Tooth

, et al. Multimorbidity patterns are differentially associated with functional ability and decline in a longitudinal cohort of older women. Age Ageing 2015; 44(5): 810–816.

85.

Hsu

H-C

. Trajectories of multimorbidity and impacts on successful aging. Exp Gerontol 2015; 66: 32–38.

86.

Vos

van den Akker

Boesten

, et al. Trajectories of multimorbidity: exploring patterns of multimorbidity in patients with more than ten chronic health problems in life course. BMC Fam Pract 2015; 16: 2.

87.

Fabbri

Zoli

, et al. Aging and the burden of multimorbidity: associations with inflammatory and anabolic hormonal biomarkers. J Gerontol: Series A. 2015; 70(1): 63–70.

88.

O’Malley

Tran

Zapalowski

, et al. Multimorbidity in women with and without osteoporosis: results from a large US retrospective cohort study 2004–2009. Osteoporos Int 2014; 25(8): 2117–2130.

89.

Kendall

Wong

Taljaard

, et al. A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario. BMC Public Health 2014; 14(1): 161.

90.

Barile

Thompson

Zack

, et al. Multiple chronic medical conditions and health-related quality of life in older adults, 2004-2006. Prev Chronic Dis 2013; 10: E162.

91.

Lappenschaar

Hommersom

Lucas

PJF

, et al. Multilevel temporal Bayesian networks can model longitudinal change in multimorbidity. J Clin Epidemiol 2013; 66(12): 1405–1416.

92.

Vanfleteren

LEGW

Spruit

Groenen

, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187(7): 728–735.

93.

Espiño-Lorenzo

Manrique-Arija

Ureña

, et al. Baseline comorbidities in patients with rheumatoid arthritis who have been prescribed biological therapy: a case control study. Reumatol Clín 2013; 9(1): 18–23.

94.

Kim

Westfall

Chamot

, et al. Multimorbidity Patterns in HIV-infected patients: the role of obesity in chronic disease clustering. JAIDS J Acquir Immune Defic Syndr 2012; 61(5): 600–605.

95.

Aarts

den Akker

van Bosma

, et al. The effect of multimorbidity on health related functioning: temporary or persistent? Results from a longitudinal cohort study. J Psychosom Res 2012; 73(3): 211–217.

96.

Freund

Kunz

Ose

, et al. Patterns of multimorbidity in primary care patients at high risk of future hospitalization. Populat Health Manage 2012; 15(2): 119–124.

97.

Quinones

Liang

Bennett

, et al.

How does the trajectory of multimorbidity vary across black, white, and mexican americans in middle and old age?

J Gerontol Ser B Psychol Sci Soc Sci 2011; 66B(6): 739–749.

98.

Schäfer

von Leitner

E-C

Schön

, et al. Multimorbidity patterns in the elderly: a new approach of disease clustering identifies complex interrelations between chronic conditions. Ross

, editor. PLoS One 2010; 5(12): e15941.

99.

Uijen

van de Lisdonk

. Multimorbidity in primary care: prevalence and trend over the last 20 years. Eur J Gen Pract 2008; 14(Suppl 1): 28–32.

100.

Raherison

Ouaalaya

E-H

Bernady

, et al. Comorbidities and COPD severity in a clinic-based cohort. BMC Pulm Med.2018; 18(1): 117.

101.

Goodwin

March

Ireland

, et al. Geographic disparities in previously diagnosed health conditions in colorectal cancer patients are largely explained by age and area level disadvantage. Front Oncol 2018; 8: 372.

102.

Levett

Wright

Fisher

. HIV and ageing: what the geriatrician needs to know. Rev Clin Gerontol 2014; 24(1): 10–24.

103.

Prados-Torres

Calderón-Larrañaga

Hancco-Saavedra

, et al. Multimorbidity patterns: a systematic review. J Clin Epidemiol 2014; 67(3): 254–266.

104.

Marengoni

Rizzuto

Wang

H-X

, et al. Patterns of chronic multimorbidity in the elderly population. J Am Geriatr Soc 2009; 57(2): 225–230.

105.

Vitry

Koczwara

, et al. Patterns of comorbidities in women with breast cancer: a Canadian population-based study. Cancer Causes Control 2019; 30(9): 931–941.

106.

Sutradhar

Yao

, et al. Smoking, drinking, diet and physical activity-modifiable lifestyle risk factors and their associations with age to first chronic disease. Int J Epidemiol 2020; 49(1): 113–130.

107.

Ashworth

Durbaba

Whitney

, et al. Journey to multimorbidity: longitudinal analysis exploring cardiovascular risk factors and sociodemographic determinants in an urban setting. BMJ Open 2019; 9(12): e031649.

108.

Demirchyan

Khachadourian

Armenian

, et al. Short and long term determinants of incident multimorbidity in a cohort of 1988 earthquake survivors in Armenia. Int J Equity Health 2013; 12(1): 68.

109.

Dhalwani

Zaccardi

O’Donovan

, et al. Association between lifestyle factors and the incidence of multimorbidity in an older English population. GERONA 2016; 72(4): 528–534.

110.

Hussin

Shahar

Din

, et al. Incidence and predictors of multimorbidity among a multiethnic population in Malaysia: a community-based longitudinal study. Aging Clin Exp Res 2019; 31(2): 215–224.

111.

Jørgensen

Aguayo-Orozco

Lademann

, et al. Age-stratified longitudinal study of Alzheimer’s and vascular dementia patients. Alzheimer’s Dementia 2020; 16(6): 908–917.

112.

Lau

Shahar

Hussin

, et al. Methodology approaches and challenges in population-based longitudinal study of a neuroprotective model for healthy longevity: LRGS TUA methodology and challenge. Geriatr Gerontol Int 2019; 19(3): 233–239.

113.

Mounce

LTA

Campbell

Henley

, et al. Predicting incident multimorbidity. Ann Fam Med 2018; 16(4): 322–329.

114.

Tomasdottir

Sigurdsson

Petursson

, et al. Does ‘existential unease’ predict adult multimorbidity? Analytical cohort study on embodiment based on the Norwegian HUNT population. BMJ Open 2016; 6(11): e012602.

115.

van den Akker

Buntinx

Metsemakers

, et al. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol 1998; 51(5): 367–375.

116.

Marengoni

Rizzuto

Fratiglioni

, et al. The Effect of a 2-year intervention consisting of diet, physical exercise, cognitive training, and monitoring of vascular risk on chronic morbidity-the FINGER randomized controlled trial. J Am Med Dir Assoc 2018; 19(4): 355–360.e1.

117.

Freisling

Viallon

Lennon

, et al. Lifestyle factors and risk of multimorbidity of cancer and cardiometabolic diseases: a multinational cohort study. BMC Med.2020; 18(1): 5.

118.

Haug

Deischinger

Gyimesi

, et al. High-risk multimorbidity patterns on the road to cardiovascular mortality. BMC Med 2020; 18(1): 44.

119.

Salloum

Chen

Yasui

, et al. Late morbidity and mortality among medulloblastoma survivors diagnosed across three decades: a report from the childhood cancer survivor study. JCO 2019; 37(9): 731–740.

120.

Castilho

Escuder

Veloso

, et al. Trends and predictors of non-communicable disease multimorbidity among adults living with HIV and receiving antiretroviral therapy in Brazil. J Intern AIDS Soc 2019; 22(1): e25233.

121.

Kivimäki

Kuosma

Ferrie

, et al. Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe. Lancet Public Health 2017; 2(6): e277–e285.

122.

Niedzwiedz

Katikireddi

Pell

, et al. Sex differences in the association between salivary telomere length and multimorbidity within the US Health & Retirement Study. Age Ageing 2019; 48(5): 703–710.

123.

Dugravot

Fayosse

Dumurgier

, et al. Social inequalities in multimorbidity, frailty, disability, and transitions to mortality: a 24-year follow-up of the Whitehall II cohort study. The Lancet Public Health 2020; 5(1): e42–e50.

124.

Singh-Manoux

Fayosse

Sabia

, et al. Clinical, socioeconomic, and behavioural factors at age 50 years and risk of cardiometabolic multimorbidity and mortality: a cohort study. Rahimi

, editor. PLoS Med 2018; 15(5): e1002571.

125.

Guaraldi

Dolci

Zona

, et al. A frailty index predicts post-liver transplant morbidity and mortality in HIV-positive patients. AIDS Res Ther 2017; 14(1): 37.

126.

Licher

Heshmatollah

van der Willik

, et al. Lifetime risk and multimorbidity of non-communicable diseases and disease-free life expectancy in the general population: a population-based cohort study. Basu

, editor. PLoS Med 2019; 16(2): e1002741.

127.

Ryan

Bray Jenkyn

Shariff

, et al. Beyond the grey tsunami: a cross-sectional population-based study of multimorbidity in Ontario. Can J Public Health 2018; 109(5–6): 845–854.

128.

Wikström

Lindström

Harald

, et al. Clinical and lifestyle-related risk factors for incident multimorbidity: 10-year follow-up of Finnish population-based cohorts 1982–2012. Eur J Intern Med 2015; 26(3): 211–216.

129.

Bjur

C-I

Ryu

, et al. Epidemiology of children with multiple complex chronic conditions in a mixed Urban-Rural US community. Hospital Pediatr 2019; 9(4): 281–290.

130.

St Sauver

Boyd

Grossardt

, et al. Risk of developing multimorbidity across all ages in an historical cohort study: differences by sex and ethnicity. BMJ Open 2015; 5(2): e006413.

131.

Wilson-Genderson

Heid

Pruchno

. Onset of multiple chronic conditions and depressive symptoms: a life events perspective. Sands

, editor. Innovat Aging 2017; 1(2): igx022.

132.

Aminisani

Stephens

Allen

, et al. Socio-demographic and lifestyle factors associated with multimorbidity in New Zealand. Epidemiol Health 2019; 42: e2020001.

133.

Hohmann

Keller

Gehring

, et al. Sex-specific incidence of asthma, rhinitis and respiratory multimorbidity before and after puberty onset: individual participant meta-analysis of five birth cohorts collaborating in MeDALL. BMJ Open Resp Res 2019; 6(1): e000460.

134.

Melis

Marengoni

Angleman

, et al. Incidence and predictors of multimorbidity in the elderly: a population-based longitudinal study. Scuteri

, editor. PLoS One 2014; 9(7): e103120.

135.

Ryan

Murphy

Boland

, et al. What is the impact of physical activity and physical function on the development of multimorbidity in older adults over time? A population-based cohort study. J Gerontol Ser A 2018; 73(11): 1538–1544.

136.

Castilho

Rebeiro

Shepherd

, et al. Mood disorders and increased risk of noncommunicable disease in adults with HIV. JAIDS J Acquir Immune Defic Syndr 2020; 83(4): 397–404.

137.

Ungprasert

Matteson

Crowson

. Increased risk of multimorbidity in patients with sarcoidosis: a population-based cohort study 1976 to 2013. Mayo Clin Proceed 2017; 92(12): 1791–1799.

138.

Jones

Mishra

. Age at natural menopause and development of chronic conditions and multimorbidity: results from an Australian prospective cohort. Hum Reprod 2020; 35(1): 203–211.

139.

Mishra

Jones

. Depressive symptoms and the development and progression of physical multimorbidity in a national Cohort of Australian women. Health Psychol 2019; 38(9): 812.

140.

Brunson

. Alluvial Plots in ggplot2.https://cran.r-project.org/web/packages/ggalluvial/vignettes/ggalluvial.html (2020, accessed 12 January 2021).

141.

Chan

van den Hout

Pujades-Rodriguez

, et al. Socio-economic inequalities in life expectancy of older adults with and without multimorbidity: a record linkage study of 1.1 million people in England. Int J Epidemiol 2019; 48(4): 1340–1351.

142.

Abad-Díez

Calderón-Larrañaga

Poncel-Falcó

, et al. Age and gender differences in the prevalence and patterns of multimorbidity in the older population. BMC Geriatr 2014; 14(1): 75.

143.

Barnes

. Mechanisms of development of multimorbidity in the elderly. Eur Respir J 2015; 45(3): 790–806.

144.

Agustí

AGN

Noguera

Sauleda

, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21(2): 347–360.

145.

Sin

Bell

Svenson

, et al. The impact of follow-up physician visits on emergency readmissions for patients with asthma and chronic obstructive pulmonary disease: a population-based study. Am J Med 2002; 112(2): 120–125.

146.

Britt

Harrison

Miller

, et al. Prevalence and patterns of multimorbidity in Australia. Med J Austr 2008; 189(2): 72–77.

147.

Taylor

Price

Gill

, et al. Multimorbidity - not just an older person’s issue. Results from an Australian biomedical study. BMC Public Health 2010; 10(1): 718.

148.

Wolff

Starfield

Anderson

. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med 2002; 162(20): 2269.

149.

Matheson

Smith

KLW

Fazli

, et al. Physical health and gender as risk factors for usage of services for mental illness. J Epidemiol Community Health 2014; 68(10): 971–978.

150.

Nabalamba

Millar Wayne

. Going to the doctor. Health Rep 2007; 18(1): 23–35.

151.

Tjepkema

. Health care use among gay, lesbian and bisexual Canadians. Health Rep 2008; 19(1): 53–64.

152.

Verhaak

PFM

Heijmans

MJWM

Peters

, et al. Chronic disease and mental disorder. Soc Sci Med 2005; 60(4): 789–797.

153.

Barnett

Mercer

Norbury

, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012; 380(9836): 37–43.

154.

García-Olmos

Salvador

Alberquilla

, et al. Comorbidity patterns in patients with chronic diseases in general practice. PLoS One 2012; 7(2): e32141.

155.

Deschênes

Kivimaki

Schmitz

. Adverse childhood experiences and the risk of coronary heart disease in adulthood: examining potential psychological, biological, and behavioral mediators in the Whitehall II Cohort study. JAHA 2021; 10(10):e019013.

156.

World Health Organization. Global status report on noncommunicable diseases 2014. Geneva: World Health Organization, 2014.

157.

Sattar

Gill

JMR

Alazawi

. Improving prevention strategies for cardiometabolic disease. Nat Med 2020; 26(3): 320–325.

158.

Twenge

Cooper

Joiner

, et al. Age, period, and cohort trends in mood disorder indicators and suicide-related outcomes in a nationally representative dataset, 2005–2017. J Abnor Psychol 2019; 128(3): 185–199.

159.

Dunlay

Chamberlain

. Multimorbidity in older patients with cardiovascular disease. Curr Cardiovasc Risk Rep 2016; 10(1): 3.

160.

Salive

. Multimorbidity in older adults. Epidemiol Rev 2013; 35(1): 75–83.

161.

Zhang

Sun

, et al. A multicenter study of multimorbidity in older adult inpatients in China. J Nutr Health Aging 2020; 24(3): 269–276.

162.

Kessler

Berglund

Demler

, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005; 62(6): 593–602.

163.

Maslow

Haydon

Ford

, et al. Young adult outcomes of children growing up with chronic illness: an analysis of the national longitudinal study of adolescent health. Arch Pediatr Adolesc Med 2011; 165(3), http://archpedi.jamanetwork.com/article.aspx?doi=10.1001/archpediatrics.2010.287 (accessed 21 December 2020).

164.

Cicero

Reisner

Merwin

, et al. The health status of transgender and gender nonbinary adults in the United States. Garcia

, editor. PLoS One 2020; 15(2): e0228765.

165.

Reisner

Hughto

JMW

. Comparing the health of non-binary and binary transgender adults in a statewide non-probability sample. PLoS One 2019; 14(8): e0221583.

166.

Laurencin

McClinton

. The COVID-19 Pandemic: a call to action to identify and address racial and ethnic disparities. J Racial Ethn Health Disparities 2020; 7(3): 398–402.

167.

Webb Hooper

Nápoles

Pérez-Stable

. COVID-19 and racial/ethnic disparities. JAMA 2020; 323(24): 2466.

168.

Paulsen

Andersen

Thomsen

, et al. Multimorbidity and blood pressure control in 37 651 hypertensive patients from Danish General Practice. JAHA 2013; 2(1). https://www.ahajournals.org/doi/10.1161/JAHA.112.004531 (accessed 21 December 2020).

169.

Wong

MCS

Wang

HHX

Cheung

CSK

, et al. Factors associated with multimorbidity and its link with poor blood pressure control among 223,286 hypertensive patients. Int J Cardiol 2014; 177(1): 202–208.

170.

Sarkar

Dodhia

Crompton

, et al. Hypertension: a cross-sectional study of the role of multimorbidity in blood pressure control. BMC Fam Pract 2015; 16(1): 98.

171.

Forman

Maurer

Boyd

, et al. Multimorbidity in older adults with cardiovascular disease. J Am College Cardiol 2018; 71(19): 2149–2161.

172.

Glynn

Buckley

Reddan

, et al. Multimorbidity and risk among patients with established cardiovascular disease: a cohort study. Br J Gen Pract 2008; 58(552): 488–494.

173.

Teljeur

Smith

Paul

, et al. Multimorbidity in a cohort of patients with type 2 diabetes. Eur J Gen Pract 2013; 19(1): 17–22.

174.

Alonso-Morán

Orueta

Esteban

JIF

, et al. The prevalence of diabetes-related complications and multimorbidity in the population with type 2 diabetes mellitus in the Basque Country. BMC Public Health 2014; 14(1): 1059.

175.

Guthrie

. Measuring and understanding Multimorbidity using routine data in the UK. In progress.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.05 MB

0.13 MB

0.38 MB